ĐẦU TƯ VÀ PHÁT TRIỂN Y TẾ VIỆT NHẬT

SOCIALIST REPUBLIC OF VIETNAM
Independence - Freedom – Happiness

No: 356-2026/CV-JVC

V/v: Explain and report on the situation of overcoming the warning securities situation

Hanoi, date 28 August 2026

CÔNG TY CỔ PHẦN ĐẦU TƯ VÀ PHÁT TRIỂN Y TẾ VIỆT NHẬT

Digitally signed by CÔNG TY CỔ PHẦN ĐẦU TƯ VÀ PHÁT TRIỂN Y TẾ VIỆT NHẬT
DN: C=VN, S=HÀ NỘI, L=Phường Láng, CN=CÔNG TY CỔ PHẦN ĐẦU TƯ VÀ PHÁT TRIỂN Y TẾ VIỆT NHẬT, OID.0.9.2342.19200300.100.1.1=MST:0101178800
Location:
Date: 2026.08.28 18:58:04+07'00'

Respectfully to: **STATE SECURITIES COMMISSION**
HO CHI MINH CITY STOCK EXCHANGE

Japan Vietnam Medical Investment and Development Joint Stock Company (Stock code: JVC) sends our sincere greeting and profound thank to your institute.

On April 5th 2023, Ho Chi Minh City Stock Exchange issued Decision No. 155/QD-SGDHCM on transferring JVC shares from control status to warning status from April 7th 2023 due to the Parent Company's after-tax profit in 2022 being VND 21.76 billion and undistributed after-tax profit as of December 31, 2022 being -1,099.98 billion based on the audited consolidated financial statements for 2022.

On 05th September 2025, JVC received Notice No. 1605/TB-SGDHCM on maintaining the warning status under Decision No. 155/QĐ-SGDHCM dated 05 April 2023, because JVC's undistributed profit after tax as of 30th June 2025 was negative, based on the reviewed consolidated semiannual financial statements for 2025.

By this dispatch, Viet Nhat Company would like to report to the Authority the measures and roadmap to overcome the situation of securities being warned as follows:

Improving the company's business situation: During its operation up to now, the Company has taken advantage of market opportunities, implemented synchronous solutions to increase revenue, control and save costs, leading to a significant improvement in business efficiency. The Company is continuing to strengthen research, analysis and market evaluation, taking full advantage of and exploiting the existing strengths within the enterprise while continuing to radically reduce costs in administration and operation but still ensuring that production and business activities are continuous and still maintain and encourage the motivation of all employees. In addition, the Company's production and business results up to 30th June 2026 continued to have positive profits, and investments also brought about clear results.

As of now, JVC has successfully launched four Diagnostic Imaging Centers (two in Hanoi, one in Vinh City and one in Ho Chi Minh City), all of which have shown initial positive results. In 2025, JVC launched another center in Vinh City. All JVC imaging centers are equipped with state-of-the-art medical equipment, including the CT-Scenaria 128-slice CT scanner and the Echelon Smart 1.5T MRI scanner, meeting standards set by the Ministry of Health. The Company collaborates with a team of Key Opinion Leaders (KOLs) to widely reach customers, helping to maintain a stable customer base with a growing trend over time. The development and expansion of the Specialized Diagnostic Imaging Clinic model is not only based on JVC's existing strengths but also effectively leverages resources such as post-partnership medical equipment, a team of engineers, and KOLs. In the next phase, JVC will continue to replicate this clinic model in key provinces across Vietnam. As of now, the Diagnostic Imaging Centers have been operating stably and efficiently.

Fiercely search for and deploy new products to increase the competitiveness of the Enterprise.

In 2026, the company will continue to implement its traditional products while expanding into interventional product lines, high-tech medical devices, cardiovascular interventions, and pharmaceutical business.

The Company is making continuous efforts every day to further develop its business operations, striving to achieve annual profitability in order to gradually offset the accumulated losses from previous years. Resolving the stock warning status remains JVC's top priority, with the goal of ensuring the maximum rights and benefits for its shareholders.

JVC would like to report to your institutes on the orientation as well as measures and roadmap to overcome the situation of securities being warned as above.

We absolutely strictly comply with the updating and disclosure of information on the above issues to your institute periodically every quarter (calculated according to the calendar year) in accordance with the provisions of the Regulations on listing and trading of listed securities.

Sincerely!

JAPAN VIETNAM MEDICAL INVESTMENT AND DEVELOPMENT JOINT STOCK COMPANY

M.S.D.N: 0101178800 - C.T.C.P
CÔNG TY CỔ PHẦN ĐẦU TƯ VÀ PHÁT TRIỂN Y TẾ VIỆT NHẬT
P. LÁNG - TP. HÀ NỘI

NGUYEN NGOC CUONG

To:

- *As Respectfully to;*
- *Archived in clerical department.*